[go: up one dir, main page]

CY1107295T1 - Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους - Google Patents

Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους

Info

Publication number
CY1107295T1
CY1107295T1 CY20081100254T CY081100254T CY1107295T1 CY 1107295 T1 CY1107295 T1 CY 1107295T1 CY 20081100254 T CY20081100254 T CY 20081100254T CY 081100254 T CY081100254 T CY 081100254T CY 1107295 T1 CY1107295 T1 CY 1107295T1
Authority
CY
Cyprus
Prior art keywords
thyroid
formulon
medications
stabilization
solid
Prior art date
Application number
CY20081100254T
Other languages
English (en)
Inventor
Spiridon Spireas
Original Assignee
Sigmapharm, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigmapharm, Inc. filed Critical Sigmapharm, Inc.
Publication of CY1107295T1 publication Critical patent/CY1107295T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Παρέχονται φαρμακευτικές φόρμουλες και μορφές δόσεων που έχουν βελτιωμένη σταθερότητα στην προκαλούμενη από την υγρασία αποικοδόμηση, όταν συγκρίνονται με συμβατικές μορφές δόσεων, ιδίως δισκία. Η ευρεσιτεχνία χαρακτηρίζεται από χαμηλής συμπιέσεως μορφές φαρμάκων του θυρεοειδούς μαζί με έκδοχα, κατά προτίμηση σε μορφές εντός κάψουλας. Σε άλλες υλοποιήσεις, σχετικώς μη-πτητικά έλαια μπορούν να αναμειχθούν με το φάρμακο και/ή τα έκδοχα για να σταθεροποιηθεί η φόρμουλα έναντι της προκαλούμενης από την υγρασία αποικοδόμησης. Υδρόφοβες κόνεις προστίθενται επίσης, προαιρετικώς, στις φόρμουλες.
CY20081100254T 2000-10-03 2008-03-05 Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους CY1107295T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23744200P 2000-10-03 2000-10-03
US09/690,973 US6855333B1 (en) 2000-10-03 2000-10-18 Stabilization of solid thyroid drug formulations
EP01971348A EP1322294B1 (en) 2000-10-03 2001-09-26 Stabilization of solid thyroid drug formulations

Publications (1)

Publication Number Publication Date
CY1107295T1 true CY1107295T1 (el) 2012-11-21

Family

ID=26930677

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100254T CY1107295T1 (el) 2000-10-03 2008-03-05 Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους

Country Status (14)

Country Link
US (1) US6855333B1 (el)
EP (1) EP1322294B1 (el)
CN (1) CN1543341A (el)
AT (1) ATE380543T1 (el)
AU (2) AU9124401A (el)
CA (4) CA2641575C (el)
CY (1) CY1107295T1 (el)
DE (1) DE60131863T2 (el)
ES (1) ES2298262T3 (el)
HK (1) HK1055260A1 (el)
MX (1) MXPA03002809A (el)
NZ (1) NZ524567A (el)
PT (1) PT1322294E (el)
WO (1) WO2002028364A2 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365745A2 (en) 2001-02-15 2003-12-03 King Pharmaceuticals, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
WO2002072069A1 (en) * 2001-03-12 2002-09-19 Novo Nordisk A/S Novel tablets and capsules and a process for its preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
US10231931B1 (en) 2018-03-23 2019-03-19 Genus Lifesciences Inc. Thyroid hormone oral dosage forms and methods of using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001211A (en) * 1974-12-02 1977-01-04 The Dow Chemical Company Pharmaceutical capsules from improved thermogelling methyl cellulose ethers
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
EP0326618A1 (en) 1987-03-04 1989-08-09 Nippon Hypox Laboratories Incorporated Medicinal composition containing albumin as carrier and process for its preparation
US4983399A (en) * 1989-10-18 1991-01-08 Eastman Kodak Company Direct compression carrier composition
US5225204A (en) * 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
DE4318577A1 (de) 1993-06-04 1994-12-08 Merck Patent Gmbh Schmiermittelfreie, arzneimittelhaltige Tabletten
US5688510A (en) 1993-11-18 1997-11-18 Nippon Shinyaku Co. Ltd. Process for producing stable medicinal composition, and pharmaceutical preparation
GB9401892D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
CA2159419C (en) 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
DE19541128C2 (de) 1995-10-27 1997-11-27 Henning Berlin Gmbh & Co Stabilisierte schilddrüsenhormonhaltige Arzneimittel
US5635209A (en) 1995-10-31 1997-06-03 Vintage Pharmaceuticals, Inc. Stabilized composition of levothyroxine sodium medication and method for its production
ES2224184T3 (es) 1995-11-14 2005-03-01 ABBOTT GMBH & CO. KG Preparaciones estabilizadas de hormonas tiroideas y metodos para su fabricacion.
DE69705516T3 (de) 1996-04-16 2004-09-30 Takeda Chemical Industries, Ltd. D-mannit und seine herstellung
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same

Also Published As

Publication number Publication date
MXPA03002809A (es) 2004-09-10
CA2641575C (en) 2014-04-08
CA2641570C (en) 2014-04-22
CA2641581C (en) 2011-11-29
AU9124401A (en) 2002-04-15
CA2423572A1 (en) 2002-04-11
US6855333B1 (en) 2005-02-15
CN1543341A (zh) 2004-11-03
EP1322294A2 (en) 2003-07-02
DE60131863T2 (de) 2008-12-11
DE60131863D1 (de) 2008-01-24
EP1322294B1 (en) 2007-12-12
CA2641570A1 (en) 2002-04-11
CA2423572C (en) 2009-01-06
WO2002028364A2 (en) 2002-04-11
AU2001291244B2 (en) 2006-09-21
ES2298262T3 (es) 2008-05-16
ATE380543T1 (de) 2007-12-15
CA2641581A1 (en) 2002-04-11
NZ524567A (en) 2004-12-24
WO2002028364A3 (en) 2002-06-06
CA2641575A1 (en) 2002-04-11
PT1322294E (pt) 2008-02-28
HK1055260A1 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
CY1107295T1 (el) Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
HK1096034A1 (en) A solid dosage form comprising a fibrate
DE60231298D1 (de) Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
SE0003449L (sv) Cancerhämmande kompositioner
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
EP1391200A4 (en) DRUG
EA200301275A1 (ru) Капсулы для ингаляции
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
ATE356612T1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
EE200200522A (et) Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina
DE60004797D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
ITRM20010226A0 (it) Dispositivo impiantabile di altezza ridotta per la somministrazione di preparati medicinali.
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
WO2003013441A3 (en) Levothyroxine compositions and methods
DK1273301T3 (da) Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration
MY141008A (en) Oral formulations of deoxypeganine and their uses
WO2004014318A3 (en) Levothyroxine compositions and methods
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
SE0203817D0 (sv) New composition
WO2005115346A3 (en) Pharmaceutical composition containing risperidone